Brazilian Regulators Face Mounting Pressure to Crack Down on Compounded GLP-1 Weight-Loss Drugs
核心洞察
ANVISA has restricted imports of biotechnological APIs like semaglutide while allowing synthetic tirzepatide imports, amid concerns over uncontrolled compounding of GLP-1 drugs in Brazil.
Pharmaceutical giants Novo Nordisk and Eli Lilly challenge the legitimacy of compounded weight-loss medications, arguing there's no evidence these formulations actually contain their patented active ingredients.
Medical societies and industry groups warn that compounded GLP-1 drugs lack proper safety studies and regulatory oversight, with clinics inappropriately substituting approved medications with unproven alternatives.
Brazilian health authorities are under increasing pressure to address the rapidly expanding market for compounded GLP-1 weight-loss medications, as pharmaceutical companies and medical societies raise serious concerns about patient safety and regulatory compliance.
Regulatory Response to Growing Market
In August 2025, Brazil's health regulator ANVISA imposed stricter import controls on GLP-1 receptor (搜索) agonist active pharmaceutical ingredients (APIs) through Order #97/2025. The directive restricted importation of biotechnological APIs like semaglutide and liraglutide to manufacturers whose ingredients have been previously reviewed during product registration. For synthetic APIs such as tirzepatide, importation remains authorized provided the drug containing the molecule is registered in Brazil.
ANVISA acknowledged in Technical Note #200/2025 that routine compounding of semaglutide and tirzepatide is "unfeasible from a sanitary perspective" due to their status as "active ingredients of high pharmaceutical complexity and high sanitary risk when compounded, particularly in sterile injectable forms, without evidence of stability, sterility, and therapeutic equivalence."
Industry Challenges to Compounded Formulations
Novo Nordisk and Eli Lilly, which hold patents for semaglutide and tirzepatide respectively, dispute the legitimacy of compounded versions. The companies state they do not sell their active ingredients to third parties, raising questions about the authenticity of compounded formulations.
"This type of import should be considered illegal, but that would require coordinated action by ANVISA and the Federal Police," said Ana Claudia Oliveira, an intellectual property specialist at the Brazilian Association of Pharmaceutical Industries (ABIFINA).
Ana Miriam Dias, chief legal officer of Novo Nordisk, criticized what she termed "industrial-scale compounding" of products with identical dosages to approved medications. "The purpose of magistral compounding is not to reproduce a product at the same dosage, and we were seeing the same dosage and large-scale production of semaglutide, which makes no sense," Dias stated.
Compounding Industry Defense
The National Association of Sterile Magistral Compounding (ANME) defended the practice, stating that tirzepatide used in compounded products is sourced from China and India. ANME president Manuela Coutinho argued that demand has grown due to shortages of high-dose weight-loss pens in Brazil.
"They're almost impossible to find, but patients need to continue treatment and increase the dosage. That's why many doctors recommend the compounded option," Coutinho explained. The association noted that compounded products are supplied in vials with different strengths and administered using syringes at physician-prescribed doses.
Safety Concerns and Medical Society Opposition
Brazilian medical societies have taken a strong stance against compounded GLP-1 medications. A joint statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Diabetes (搜索) Society (SBD), and Brazilian Association for the Study of Obesity (搜索) and Metabolic Syndrome (ABESO) called compounding a "growing, concerning, and dangerous practice" lacking regulatory and scientific backing.
Nelson Mussolini, executive president of pharmaceutical industry association Sindusfarma, emphasized that "there are no clinical studies demonstrating that these specific dosages are safe and effective." He noted that unlike pharmaceutical companies, compounding pharmacies are not subject to pharmacovigilance systems that track adverse effects.
Clinical Practice Concerns
Medical clinics across Brazil are increasingly offering compounded weight-loss treatments, with some preventing patients from accessing prescriptions for original medications. Reports indicate clinics are improperly using Mounjaro and Ozempic trademarks in advertising, potentially misleading patients about product equivalence.
"Publishing rules is not enough. There needs to be more effective enforcement. Clinics are popping up all over Brazil with highly seductive marketing," Mussolini warned, noting that some companies are training physicians to become "social media influencers" to sell unproven protocols.
International Precedent and Enforcement
The situation mirrors recent U.S. regulatory action, where the FDA issued over 50 warning letters to compounding pharmacies marketing GLP-1 drugs in September 2025. The FDA categorically stated that claims of equivalent efficacy and safety between compounded and approved products are "false and misleading."
Compounding of weight-loss injections has already been banned in countries including Australia and South Africa, arguments that Novo Nordisk has cited in requesting ANVISA action.
Current Market Dynamics
Brazil currently has only 35 sterile compounding pharmacies authorized to produce these medications, which must meet stricter sterilization standards than traditional compounding facilities. Under Brazilian regulations, compounding is permitted only when patients need different dosages or have medical contraindications to approved product components.
The regulatory tightening has not yet affected sterile compounding pharmacies, which currently report no shortages of raw materials. However, with restrictions on biotechnological APIs, industry observers expect increased focus on tirzepatide compounding, potentially exacerbating regulatory challenges.